Alzheimer's drug studies will continue

20 Things To Know About Alzheimer's Disease

Please Help Support Alzheimer's Research Today! 

Your Alzheimer's donation will help billions live without it.

Improve Your Brain

Alzheimer's facts

DONATE NOW

(Targacept)

Alzheimer’s Disease is the most common form of dementia and it is on the rise. Over the next 20 years, the current number of people affected by dementia worldwide is estimated to double from 36 million to 72 million. 

Targacept Inc. said Thursday that its partner AstraZeneca PLC is preparing to run midstage clinical trials of an experimental Alzheimer's disease treatment that Targacept developed.

Targacept said AstraZeneca will study a combination of the drug, now called AZD1446, and Aricept, an older Alzheimer's disease drug, on patients with mild to moderate Alzheimer's disease. AZD1446 will be studied as an adjunct treatment, or a drug intended to make another drug more effective. Targacept and AstraZeneca have been collaborating since 2005.

Targacept is based in Winston-Salem, N.C., and AstraZeneca in London. The companies are also studying an adjunct depression treatment designated TC-5214. That drug has failed in two late-stage clinical trials, but they are running two other studies.

Shares of Targacept rose 10 cents to $5.72 in afternoon trading, while U.S. shares of AstraZeneca slipped 78 cents to $46.69.  Continue to read: rdmag.com

TODAY'S PHOTO

Gold kiwifruit may slash severity of common cold

Eating a couple of gold kiwifruit every day may reduce the severity of symptoms of the common cold, says new data from New Zealand. Read more: nutraingredients.com 

Беларусь ТВ

Posted YVN (AMYLOID @ PHOTO).